OTC: PPCB - Propanc Biopharma, Inc.

Yield per half year: -84.13%
Dividend yield: 0%
Sector: Healthcare

Share chart Propanc Biopharma, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes.

more details
The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

ISIN US74346N4043
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.propanc.com
Цена ао 2.75
Change price per day: 0% (2.8)
Change price per week: 0% (2.8)
Change price per month: -42.81% (4.8956)
Change price per 3 month: +1.45% (2.76)
Change price per half year: -84.13% (17.6471)
Change price per year: +399 900% (0.0007)
Change price per 3 year: +31 718.18% (0.0088)
Change price per 5 year: +18 818.92% (0.0148)
Change price per year to date: -76.2% (11.7647)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV -0.0243 0
P/E 0 0
EV/EBITDA -0.8072 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -2743.97 0
ROE, % 52.8 10
Total: 3.17

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.7513 10
Total: 8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % -59.29 0
Yield EPS, % 6893.88 10
Total: 2
More



Head Job title Payment Year of birth
Mr. James Nathanielsz Executive Chairman, CEO, CFO, Treasurer & Secretary 430.28k 1974 (51 year)
Dr. Julian Norman Kenyon ChB, M.D., MB Chief Scientific Officer, CTO & Director 35.99k 1948 (77 years)
Prof. Klaus Kutz Chief Medical Officer & Member of Scientific Advisory Board 18.23k

Address: Australia, Camberwell. VIC, 302. 6 Butler Street - open in Google maps, open in Yandex maps
Website: https://www.propanc.com